Sudeep Pharma IPO
IPO Listing Details
- Listing Date
28 Nov 2025
- Listing Price
₹733.95
- Listing Change
23.77%
- Last Traded Price
₹628.75
Sudeep Pharma IPO Details
-
Open Date
21 Nov 2025
-
Close Date
25 Nov 2025
-
Listing Date
28 Nov 2025
- IPO Price Range
₹ 563 to ₹ 593
- IPO Size
₹ 895 Cr
- Listing Exchange
BSE NSE
Sudeep Pharma IPO Timeline
Sudeep Pharma IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 21-Nov-2025 | 0.09 | 3.01 | 1.53 | 1.43 |
| 24-Nov-2025 | 0.13 | 12.03 | 5.02 | 5.13 |
| 25-Nov-2025 | 213.08 | 116.72 | 15.65 | 93.71 |
Last Updated: 25 November 2025 5:18 PM by 5paisa
Sudeep Pharma Limited, launching a ₹895 Cr IPO, is a leading manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, supplying over 200 products to customers in more than 100 countries. With six manufacturing facilities and a total capacity of 50,000 MT, the company specialises in calcium, iron, magnesium, zinc, potassium, and sodium minerals. Supported by strong R&D with in-house labs and pilot-scale units, its portfolio spans pharmaceutical, food and nutrition, specialty ingredients, and triturates.
Established in: 1989
Managing Director: Sujit Jaysukh Bhayani
Peers:
No Listed Peer
Sudeep Pharma Objectives
1. The company allocates ₹75.81 crores for new machinery.
2. Additionally, funds are used for general corporate purposes.
Sudeep Pharma IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹895 Cr |
| Offer For Sale | ₹800 Cr |
| Fresh Issue | ₹95 Cr |
Sudeep Pharma IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | 14,075 |
| Retail (Max) | 13 | 325 | 1,92,725 |
| S-HNI (Min) | 14 | 350 | 1,97,050 |
| S-HNI (MAX) | 67 | 1,675 | 9,93,275 |
| B-HNI (Min) | 68 | 1,700 | 9,57,100 |
Sudeep Pharma IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 213.08 | 30,18,553 | 64,31,88,450 | 38,141.08 |
| Non-Institutional Buyers | 116.72 | 22,63,912 | 26,42,36,925 | 15,669.25 |
| bNII (bids above ₹10L) | 134.91 | 15,09,275 | 20,36,19,700 | 12,074.65 |
| sNII (bids below ₹10L) | 80.33 | 7,54,637 | 6,06,17,225 | 3,594.60 |
| Retail Investors | 15.65 | 52,82,462 | 8,26,52,350 | 4,901.28 |
| Total** | 93.71 | 1,05,64,927 | 99,00,77,725 | 58,711.61 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 428.74 | 459.28 | 501.10 |
| EBITDA | 98.64 | 187.76 | 199.28 |
| PAT | 62.32 | 133.15 | 138.69 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 190.10 | 238.50 | 293.05 |
| Share Capital | 1.41 | 1.41 | 9.72 |
| Total Borrowing | 82.26 | 75.03 | 135.25 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 48.90 | 65.69 | 48.73 |
| Net Cash Generated From / (used in) Investing Activities | -50.02 | -49.28 | -78.76 |
| Net Cash Generated From / (used in) Financing Activities | -9.78 | -12.74 | 52.70 |
| Net Increase (Decrease) in Cash and Cash Equivalents | -11.40 | 3.67 | 22.67 |
Strengths
1. Wide global presence across 100+ countries.
2. Strong R&D with advanced in-house labs.
3. Diverse portfolio across minerals and excipients.
4. Large capacity across six modern facilities.
Weaknesses
1. High dependence on mineral-based product demand.
2. Capital-intensive manufacturing increases fixed costs.
3. Limited direct consumer brand visibility globally.
4. Complex compliance burden across multiple markets.
Opportunities
1. Growing demand for specialised nutrition ingredients.
2. Rising pharma excipient needs in emerging markets.
3. Scope to expand premium mineral formulations.
4. Potential for strategic global partnerships.
Threats
1. Regulatory changes affecting product approvals.
2. Commodity price fluctuations impacting margins.
3. Increasing competition from global suppliers.
4. Supply chain disruptions affecting operations.
1. Strong global presence across diverse end industries.
2. Expanding capacity supports sustained future growth.
3. Robust R&D enhances product innovation potential.
4. Diversified portfolio reduces sector-specific risks.
Sudeep Pharma Ltd operates across pharmaceutical excipients, food-grade minerals, and nutritional ingredients, serving over 100 countries with a robust portfolio of 200+ products. With six manufacturing facilities and strong R&D capabilities, the company is well positioned to benefit from rising global demand for high-quality mineral salts. Its capacity expansion plans, technological upgrades, and diversified customer base further strengthen its long-term growth trajectory.
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Sudeep Pharma IPO opens from November 21, 2025 to November 25, 2025.
The size of Sudeep Pharma IPO is ₹895 Cr.
The price band of Sudeep Pharma IPO is fixed at ₹563 to ₹593 per share.
To apply for Sudeep Pharma IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Sudeep Pharma IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Sudeep Pharma IPO is of 25 shares and the investment required is ₹14,075.
The share allotment date of Sudeep Pharma IPO is November 26, 2025.
The Sudeep Pharma IPO will likely be listed on 28 November 2025.
ICICI Securities Ltd is the book running lead manager for Sudeep Pharma IPO.
Sudeep Pharma IPO plans to utilise the raised capital from the IPO for:
The company allocates ₹75.81 crores for new machinery.
Additionally, funds are used for general corporate purposes.